Healius (ASX:HLS) share price falls despite $300m acquisition

Healius is making an acquisition…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Healius Ltd (ASX: HLS) share price is on course to end the week in the red.

At the time of writing, the healthcare company's shares are down 2% to $5.17.

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.

Image source: Getty Images

Why is the Healius share price falling?

Investors have been selling down the Healius share price today after it announced an agreement to acquire the entire issued capital of Agilex. It is one of Australia's leading bioanalytical laboratories.

According to the release, the transaction values Agilex at an enterprise value of $301.3 million.

The release explains that Agilex has a high margin and capital-light business model with immediate and long-term growth potential. This will be enhanced by Healius' experience operating laboratory businesses and by increased financial capacity to support the delivery of the growth strategy.

Management sees Agilex as a long-term strategic acquisition that provides the company with a platform for growth into the global clinical trials sector and a structurally attractive, higher growth, higher margin adjacency.

Agilex is expected to generate revenue and EBITDA in the range of $36-40 million and $14-16 million, respectively, in calendar year 2022, with strong future earnings growth anticipated. Judging by the Healius share price reaction, investors may believe this makes the transaction value a little on the rich side.

Nevertheless, the acquisition is expected to deliver low single digit earnings per share accretion in the first full year of ownership.

Healius' Managing Director and CEO, Dr Malcolm Parmenter, said: "The acquisition of Agilex is an exciting opportunity for Healius. Agilex has a talented scientific team with state-of-the-art laboratories and culturally complements Healius. It's a logical entry point for Healius into the attractive global bioanalytical laboratory services market, and one in which Australia and Agilex, in particular, is wellplaced to service."

"We see Agilex as a long-term strategic acquisition that adds a global orientation to the Healius network. A business that is growing fast, in a fast-growing market. Agilex is well placed to realise a material step-change in earnings growth over the near to medium-term," he added.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Doctor with stethoscope around neck shrugging.
Earnings Results

CSL reports on 18 August. Can the healthcare giant arrest the slide?

A make-or-break result for Australia's fallen biotech giant.

Read more »

An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.
Healthcare Shares

Regis Healthcare acquires Royal Freemasons' Victorian home care business

Regis Healthcare has announced the acquisition of Royal Freemasons’ home care business, expanding its client base and annualised home care…

Read more »

Two researchers discussing results of a study with each other.
Healthcare Shares

CSL vs Telix shares: Which is the better buy?

One valuation immediately caught my attention, while the other requires considerably more confidence in future growth.

Read more »

A healthcare worker wearing a white coat holds his fingers to his mouth looking worried as healthcare stocks like Cochlear crash today
Healthcare Shares

This ASX healthcare stock trades at its cheapest multiple in a decade

A quality business at a decade-low multiple. What gives?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Healthcare Shares

CSL shares bounced in July after a brutal year: What's next?

Can CSL sustain July's rebound when it reports FY2026 results this month.

Read more »

Three businesswomen collaborate around a table.
Healthcare Shares

Clarity Pharmaceuticals reports clinical progress in June 2026 quarter

Clarity Pharmaceuticals reported $178.3 million in cash and strong clinical progress for the June 2026 quarter.

Read more »

A male doctor and a woman in scrubs in the foreground smile.
Healthcare Shares

Mesoblast FY26 earnings: Ryoncil revenue up, new trial milestones for ASX:MSB

Mesoblast reported a strong full year with US$115 million in Ryoncil revenue and advanced key clinical trials for future growth.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

CSL launches clinical trials for new plasma manufacturing process

CSL will launch clinical trials of its new Horizon 2 plasma process in 2027, seeking enhanced yields and regulatory approvals.

Read more »